Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
|Articles|October 26, 2014
Sunday Funny: Too Many Choices
Author(s)Jon Carter
Okay, so the last choice isn't really an option, but you get the picture when it comes to the variety of ultrasound imaging.
Advertisement
[[{"type":"media","view_mode":"media_crop","fid":"28797","attributes":{"alt":"","class":"media-image","id":"media_crop_6943084700033","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2941","media_crop_rotate":"0","media_crop_scale_h":"567","media_crop_scale_w":"590","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
Advertisement
Related to this article
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Joint guidance from the AHA, AAP, ACOG, and SMFM organizes cardiovascular prevention for girls and women around 4 female life stages.
Experts address COVID-19 vaccine myths, safety evidence, and how to frame the benefits of vaccination in pregnancy.
Experts look ahead to new maternal vaccines and how to counsel patients on receiving several in one pregnancy.
Experts discuss common patient concerns about vaccination in pregnancy and strategies to improve uptake.
Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
FDA removes boxed warnings from 3 more menopausal hormone therapy products
2
ACOG advises against GLP-1 receptor agonists during pregnancy
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Chrisandra Shufelt, MD, on cardiovascular risk assessment and menopause care
5